

CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/404,474,
5 filed on October 5, 2016. The entire teachings of the aforementioned application are
incorporated herein by reference.

FIELD OF THE INVENTION

This disclosure relates to solid forms of compounds capable of activating PPAR δ for
use in drug substance and drug product development, and related compositions and methods.

BACKGROUND OF THE INVENTION


Peroxisome proliferator-activated receptor delta (PPAR δ) is a nuclear receptor that is
capable of regulating mitochondria biosynthesis. As shown in PCT/2014/033088,
incorporated herein by reference, modulating the activity of PPAR δ is useful for the
treatment of diseases, developmental delays, and symptoms related to mitochondrial
15 dysfunction, such as Alpers Disease, MERRF-Myoclonic epilepsy and ragged-red fiber
disease, Pearson Syndrome, and the like. Modulation PPAR δ activity is effective in the
treatment of other conditions, such as muscular diseases, demyelinating diseases, vascular
diseases, and metabolic diseases. Indeed, PPAR δ is an important biological target for
compounds used to help treat and prevent mitochondrial diseases, muscle-related diseases
20 and disorders, and other related conditions.

Compound A of Formula (I) and Compound B of Formula (II) are PPAR δ agonists.
There is a need for salt forms of these compounds that are crystalline and otherwise have
physical properties that are amenable to large scale manufacture. There is also a need for
pharmaceutical formulations in which these drug candidates are stable and are effectively
25 delivered to the patient.

SUMMARY

Provided herein, *inter alia*, are salts of Compound A and Compound B and
compositions comprising such compounds that are useful for increasing PPAR δ activity.


In one aspect of the present disclosure, there is provided a compound of Formula (I):



Formula (I),

in the form of a hemisulfate salt.

5 In another aspect of the present disclosure, there is provided a compound of Formula (II):



Formula (II),

in the form of a meglumine salt or a hydrate of the meglumine salt.

10 In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient.

In another aspect of the present disclosure, there is provided a therapeutically effective amount of a compound disclosed herein, or a pharmaceutical composition disclosed
15 herein for use in therapy.


In a further aspect of the present disclosure, there is provided a use of a therapeutically effective amount of a compound disclosed herein, or a pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the medicament is to be
20 administered to the subject in need thereof, wherein the PPAR δ related disease is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass

disorder, a mitochondrial disease, a beta oxidation disease, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease.

In another aspect of the present disclosure, there is provided a use of a therapeutically effective amount of a compound disclosed herein, or a pharmaceutical composition
5 comprising a compound disclosed herein and a pharmaceutically acceptable excipient, in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the PPAR δ related disease or condition is Duchenne Muscular Dystrophy.

In a further aspect of the present disclosure, there is provided a use of a therapeutically effective amount of a compound disclosed herein, or a pharmaceutical
10 composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient, in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the PPAR δ related disease or condition is acute kidney injury.


In one example, provided herein is Compound A of the Formula (I):



(I)

5 in the form of a hemisulfate salt. In one example, the hemisulfate salt of Compound A is crystalline. Thus, in one example, the crystalline the hemisulfate salt of Compound A is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1 or FIG. 2.

In another example, provided herein is Compound B of the Formula (II):



(II)

10

in the form of a meglumine salt or a hydrated form of the meglumine salt.

15

Pharmaceutical compositions of the salts of Compound A and Compound B also are disclosed herein. Particular examples comprise a pharmaceutically acceptable carrier or excipient and one or more of the disclosed compounds. The pharmaceutical compositions of the present disclosure can be used in therapy, *e.g.*, for treating a PPAR δ -related disease or condition in a subject.

Another example comprises treating a PPAR δ -related disease or condition in a subject by administering to the subject a therapeutically effective amount of one or both of the disclosed compounds, or a pharmaceutical composition comprising the compound(s).

20

Also provided herein is the use of one or more of the disclosed compounds, or a pharmaceutical composition comprising one or both of the disclosed compounds, for the preparation of a medicament for the treatment of a PPAR δ -related disease or condition.

In another embodiment provided herein, the disclosed compounds or a pharmaceutical composition comprising one or both of the disclosed compounds are for use in treating a PPAR δ -related disease or condition.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1 depicts the X-ray powder diffraction pattern of Compound A hemisulfate form 1.

 FIG. 2 depicts the X-ray powder diffraction pattern of Compound A hemisulfate form 2.

DETAILED DESCRIPTION OF THE INVENTION


10 Peroxisome proliferator-activated receptor delta (PPAR- δ), also known as peroxisome proliferator-activated receptor beta (PPAR- β) or as NR1C2 (nuclear receptor subfamily 1, group C, member 2), refers to a nuclear receptor protein that functions as a transcription factor regulating the expression of genes. PPAR δ (OMIM 600409) sequences are publically available, for example from GenBank® sequence database (*e.g.*, accession numbers
15 NP_001165289.1 (human, protein) NP_035275 (mouse, protein), NM_001171818 (human, nucleic acid) and NM_011145 (mouse, nucleic acid)).

 Ligands of PPAR δ , such as Compound A and Compound B, can promote myoblast proliferation after injury, such as injury to skeletal muscle. As such, as shown in PCT/2014/033088, incorporated herein by reference, modulating the activity of PPAR δ is
20 useful for the treatment of diseases, developmental delays, and symptoms related to mitochondrial dysfunction, such as Alpers Disease, MERRF-Myoclonic epilepsy and ragged-red fiber disease, Pearson Syndrome, and the like. Modulation PPAR δ activity is effective in the treatment of other conditions, such as muscular diseases, demyelinating diseases, vascular diseases, and metabolic diseases. Indeed, PPAR δ is an important biological target for
25 compounds used to help treat and prevent mitochondrial diseases, muscle-related diseases and disorders, and other related conditions.

 Herein, the phrase “PPAR δ agonist” refers to substances that increase the activity of PPAR δ . Substances can be tested for their PPAR δ agonist activity by contacting the substance with cells expressing PPAR δ , detecting their binding with PPAR δ and then
30 detecting signals that serve as the indicator of the activation of PPAR δ . Example 1a provides an assay showing that Compound A and Compound B activate PPAR δ .

Compounds of the Invention

Provided herein is a hemisulfate salt of (*R*)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-1-yl)methyl)phenoxy)hexanoic acid, *i.e.*, Compound A of the Formula (I):




Formula (I).

In some embodiments, the hemisulfate salt of Compound A is crystalline.

Also provided herein are methods of making a hemisulfate salt of Compound A, particularly a crystalline hemisulfate salt of Compound A. For example, upon formation by a reaction between Compound A and sulfuric acid in acetonitrile or 2-propanol, the hemisulfate salt of the compound can be isolated from the reaction mixture by crystallization (see, *e.g.*, Example 3). Accordingly, in one embodiment, provided herein is a method of making the hemisulfate salt of Compound A, the method comprising the step of reacting Compound A, with sulfuric acid in a solvent to form the hemisulfate salt of Compound A. In a particular embodiment, the solvent comprises acetonitrile. Alternatively, the solvent comprises 2-propanol. The synthesis of Compound A is described in Example 2a.

Also provided herein is a meglumine salt of (*R*)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-imidazol-1-yl)methyl)phenoxy)hexanoic acid, *i.e.*, Compound B of the Formula (II):



Formula (II).

Compound B may also be provided as a hydrate of the meglumine salt. In a particular embodiment, the meglumine salt of Compound B is provided in monohydrate form, *i.e.*, the meglumine salt of Compound B is complexed with water in a one-to-one molar ratio. In

other embodiments, the meglumine salt of Compound B is provided in unhydrated form. The term “unhydrated form” means substantially no water is complexed with the compound, *e.g.*, less than 0.05 equivalents and preferably less than 0.01 equivalents of water relative to the compound.

Also provided are methods of making a meglumine salt of Compound B. For example, upon formation by a reaction between Compound B and meglumine in a solvent such as 2-propanol or acetonitrile, the meglumine salt of Compound B can be isolated from the reaction mixture (see, *e.g.*, Example 11).

Also provided are methods of making a hydrate of the meglumine salt of Compound B. For example, upon formation by a reaction between Compound B and meglumine in an aqueous solvent mixture such as tetrahydrofuran and water, the hydrate of the meglumine salt of Compound B can be isolated from the reaction mixture (see, *e.g.*, Example 12).

The synthesis of Compound B is described in Example 2b.

Polymorphic Forms of the Hemisulfate Salt of Compound A

The hemisulfate salt of Compound A can exist in one of at least two polymorphic forms, *i.e.*, Compound A hemisulfate form 1 and Compound A hemisulfate form 2. Compound A hemisulfate form 1 possesses acceptable crystallinity and melting point (Example 6); stability and hygroscopicity (Example 10); and solubility and form control (Example 7). As shown in Example 10, Compound A hemisulfate form 1 was determined to be more thermodynamically stable than Compound A hemisulfate form 2.

Compound A hemisulfate form 1 is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1. Specifically, Compound A hemisulfate form 1 is characterized by a X-ray powder diffraction pattern comprising one or more characteristic peaks expressed in degrees-2-theta (± 0.2) as listed in the Table 3 (Example 6).

In an embodiment, Compound A hemisulfate form 1 is characterized by a first X-ray powder diffraction pattern comprising characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $7.3 \pm 0.2^\circ$, $14.7 \pm 0.2^\circ$, $19.1 \pm 0.2^\circ$, and $22.3 \pm 0.2^\circ$. In one embodiment, this first X-ray powder diffraction pattern further comprises characteristic peaks expressed in having peaks expressed in degrees-2-theta one or more of angles $8.3 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, $16.5 \pm 0.2^\circ$, $19.7 \pm 0.2^\circ$, or $25.8 \pm 0.2^\circ$. In a certain embodiment, this first X-ray powder diffraction pattern comprising characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $7.3 \pm 0.2^\circ$, $8.3 \pm 0.2^\circ$, $14.7 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, $16.5 \pm 0.2^\circ$, $19.1 \pm 0.2^\circ$, $19.7 \pm 0.2^\circ$, $22.3 \pm 0.2^\circ$, and $25.8 \pm 0.2^\circ$.

This first X-ray powder diffraction pattern can also further comprise an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at one or more of angles $13.0\pm0.2^\circ$, $17.3\pm0.2^\circ$, $23.8\pm0.2^\circ$, $24.5\pm0.2^\circ$, $24.9\pm0.2^\circ$, $26.3\pm0.2^\circ$, or $27.8\pm0.2^\circ$. In a certain embodiment, this first X-ray powder diffraction pattern comprising characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $7.3\pm0.2^\circ$, $8.3\pm0.2^\circ$, $13.0\pm0.2^\circ$, $14.7\pm0.2^\circ$, $15.8\pm0.2^\circ$, $16.5\pm0.2^\circ$, $17.3\pm0.2^\circ$, $19.1\pm0.2^\circ$, $19.7\pm0.2^\circ$, $22.3\pm0.2^\circ$, $23.8\pm0.2^\circ$, $24.5\pm0.2^\circ$, $24.9\pm0.2^\circ$, $25.8\pm0.2^\circ$, $26.3\pm0.2^\circ$, and $27.8\pm0.2^\circ$.

In a specific embodiment, this first X-ray powder diffraction pattern comprises peaks expressed in degrees-2-theta at angles $7.3\pm0.2^\circ$, $8.3\pm0.2^\circ$, $13.0\pm0.2^\circ$, $14.7\pm0.2^\circ$, $15.8\pm0.2^\circ$, $16.5\pm0.2^\circ$, $17.3\pm0.2^\circ$, $19.2\pm0.2^\circ$, $19.7\pm0.2^\circ$, $20.7\pm0.2^\circ$, $22.3\pm0.2^\circ$, $23.8\pm0.2^\circ$, $24.5\pm0.2^\circ$, $24.9\pm0.2^\circ$, $25.8\pm0.2^\circ$, $26.3\pm0.2^\circ$, $27.8\pm0.2^\circ$, $28.5\pm0.2^\circ$, $29.6\pm0.2^\circ$, and $33.7\pm0.2^\circ$.

Compound A hemisulfate form 2 is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 2. Specifically, Compound A hemisulfate form 2 is characterized by a X-ray powder diffraction pattern comprising one or more characteristic peaks expressed in degrees-2-theta (±0.2) as listed in the Table 5 (Example 8).

In an embodiment, Compound A hemisulfate form 2 can be characterized by a second X-ray powder diffraction pattern comprising characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $6.7\pm0.2^\circ$, $13.5\pm0.2^\circ$, $17.4\pm0.2^\circ$, and $18.1\pm0.2^\circ$. In one embodiment, this second X-ray powder diffraction pattern further comprises characteristic peaks expressed in having peaks expressed in degrees-2-theta one or more of angles $14.5\pm0.2^\circ$, $16.\pm0.2^\circ$, $22.4\pm0.2^\circ$, 23.2 , or $23.4 \pm0.2^\circ$. In a certain embodiment, this second X-ray powder diffraction pattern comprises characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $6.7\pm0.2^\circ$, $13.5\pm0.2^\circ$, $14.5\pm0.2^\circ$, $16.\pm0.2^\circ$, $17.4\pm0.2^\circ$, $18.1\pm0.2^\circ$, $22.4\pm0.2^\circ$, 23.2 , and $23.4 \pm0.2^\circ$.

This second X-ray powder diffraction pattern can also further comprise an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at one or more of angles $10.1\pm0.2^\circ$, $11.1\pm0.2^\circ$, $14.2\pm0.2^\circ$, $14.8\pm0.2^\circ$, $16.9\pm0.2^\circ$, $19.0\pm0.2^\circ$, $25.0\pm0.2^\circ$, $26.8\pm0.2^\circ$, or $27.4 \pm0.2^\circ$. In a certain embodiment, this second X-ray powder diffraction pattern comprises characteristic peaks expressed in having peaks expressed in degrees-2-theta at angles $6.7\pm0.2^\circ$, $10.1\pm0.2^\circ$, $11.1\pm0.2^\circ$, $13.5\pm0.2^\circ$, $14.2\pm0.2^\circ$, $14.5\pm0.2^\circ$, $14.8\pm0.2^\circ$, $16.\pm0.2^\circ$, $16.9\pm0.2^\circ$, $17.4\pm0.2^\circ$, $18.1\pm0.2^\circ$, $19.0\pm0.2^\circ$, $22.4\pm0.2^\circ$, 23.2 , $23.4 \pm0.2^\circ$, $25.0\pm0.2^\circ$, $26.8\pm0.2^\circ$, and $27.4 \pm0.2^\circ$.

In a specific embodiment, the second X-ray powder diffraction pattern comprises peaks expressed in degrees-2-theta at angles $6.7\pm0.2^\circ$, $10.1\pm0.2^\circ$, $11.1\pm0.2^\circ$, $13.5\pm0.2^\circ$,

14.2±0.2°, 14.5±0.2°, 14.8±0.2°, 16.1±0.2°, 16.9±0.2°, 17.4±0.2°, 18.1±0.2°, 19.0±0.2°, 19.9±0.2°, 22.4±0.2°, 23.2±0.2°, 23.4±0.2°, 25.0±0.2°, 26.8±0.2°, 27.4±0.2°, and 29.4±0.2°.

In one embodiment, the crystalline hemisulfate salt of Compound A is substantially free from impurities. In another embodiment, the crystalline hemisulfate salt of Compound A comprises less than 10% by weight total impurities. In another embodiment, provided herein is the crystalline hemisulfate salt of Compound A comprises less than 5% by weight total impurities. In another embodiment, the crystalline hemisulfate salt of Compound A comprises less than 1% by weight total impurities. In yet another embodiment, the crystalline hemisulfate salt of Compound A comprises less than 0.1% by weight total impurities.

In certain embodiments, the X-ray powder diffraction pattern of the crystalline hemisulfate salt of Compound A is collected using Cu K alpha (1.5406 Angstrom) radiation.

In another embodiment, provided herein is the crystalline hemisulfate salt of Compound A that is substantially free from amorphous hemisulfate salt of Compound A. As used herein, the term “substantially free from amorphous hemisulfate salt of Compound A” means that the crystalline hemisulfate salt of Compound A contains no significant amount of amorphous hemisulfate salt of Compound A. In certain embodiments, at least about 90% by weight of the crystalline hemisulfate salt of Compound A is free from amorphous hemisulfate salt of Compound A. In other embodiments, at least about 95% by weight of the crystalline hemisulfate salt of Compound A is free from amorphous hemisulfate salt of Compound A. In yet other embodiments, at least about 99% by weight of the crystalline hemisulfate salt of Compound A is free from amorphous hemisulfate salt of Compound A. In still other embodiments, at least about 99.9% by weight of the crystalline hemisulfate salt of Compound A is free from amorphous hemisulfate salt of Compound A.

In another embodiment, provided herein is the crystalline hemisulfate salt of Compound A substantially free from other crystalline forms of hemisulfate salt of Compound A. As used herein, the term “substantially free from other crystalline forms of hemisulfate salt of Compound A” means that the crystalline Compound A contains no significant amount of other crystalline forms of hemisulfate salt of Compound A. In certain embodiments, at least about 90% by weight of the crystalline hemisulfate salt of Compound A is free of other crystalline forms.

In other embodiments, at least about 95% by weight of the crystalline hemisulfate salt of Compound A is free of other crystalline forms. In yet other embodiments, at least about 99% by weight of the crystalline hemisulfate salt of Compound A is free of other crystalline

forms. In still other embodiments, at least about 99.9% by weight of the crystalline hemisulfate salt of Compound A is free of other crystalline forms.

Methods of Treatment

5 Methods of treating a PPAR δ -related disease or condition in a subject are disclosed. The methods can include administering to the subject a therapeutically effective amount of one or more compounds or compositions provided herein.

 In one embodiment, the PPAR δ -related disease is a mitochondrial disease. Examples of mitochondrial diseases include, but are not limited to, Alpers Disease, CPEO-Chronic
10 progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes, MERRF-Myoclonic epilepsy and ragged-red fiber disease, NARP-neurogenic muscle weakness, ataxia, and retinitis pigmentosa, and Pearson Syndrome.

 In other embodiments, the PPAR δ -related disease is a vascular disease (such as a
15 cardiovascular disease or any disease that would benefit from increasing vascularization in tissues exhibiting impaired or inadequate blood flow). In other embodiments, the PPAR δ -related disease is a muscular disease, such as a muscular dystrophy. Examples of muscular dystrophy include but are not limited to Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy,
20 facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy.

 In some embodiments, the PPAR δ -related disease or condition is a demyelinating disease, such as multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, or Guillian-Barre
25 syndrome.

 In other embodiments, the PPAR δ -related disease is a metabolic disease. Examples of metabolic diseases include but are not limited to obesity, hypertriglyceridemia, hyperlipidemia, hypoalphalipoproteinemia, hypercholesterolemia, dyslipidemia, Syndrome X, and Type II diabetes mellitus.

30 In yet other embodiments, the PPAR δ -related disease is a muscle structure disorder. Examples of a muscle structure disorders include, but are not limited to, Bethlem myopathy, central core disease, congenital fiber type disproportion, distal muscular dystrophy (MD), Duchenne & Becker MD, Emery-Dreifuss MD, facioscapulohumeral MD, hyaline body myopathy, limb-girdle MD, a muscle sodium channel disorders, myotonic chondrodystrophy,

myotonic dystrophy, myotubular myopathy, nemaline body disease, oculopharyngeal MD, and stress urinary incontinence.

In still other embodiments, the PPAR δ -related disease is a neuronal activation disorder. Examples of neuronal activation disorders include, but are not limited to, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Guillain-Barre syndrome, Lambert-Eaton syndrome, multiple sclerosis, myasthenia gravis, nerve lesion, peripheral neuropathy, spinal muscular atrophy, tardy ulnar nerve palsy, and toxic myoneural disorder.

In other embodiments, the PPAR δ -related disease is a muscle fatigue disorder. Examples of muscle fatigue disorders include, but are not limited to chronic fatigue syndrome, diabetes (type I or II), glycogen storage disease, fibromyalgia, Friedreich's ataxia, intermittent claudication, lipid storage myopathy, MELAS, mucopolysaccharidosis, Pompe disease, and thyrotoxic myopathy.

In some embodiments, the PPAR δ -related disease is a muscle mass disorder. Examples of muscle mass disorders include, but are not limited to, cachexia, cartilage degeneration, cerebral palsy, compartment syndrome, critical illness myopathy, inclusion body myositis, muscular atrophy (disuse), sarcopenia, steroid myopathy, and systemic lupus erythematosus.

In other embodiments, the PPAR δ -related disease is a beta oxidation disease. Examples of beta oxidation diseases include, but are not limited to, systemic carnitine transporter, carnitine palmitoyltransferase (CPT) II deficiency, very long- chain acyl- CoA dehydrogenase (LCHAD or VLCAD) deficiency, trifunctional enzyme deficiency, medium - chain acyl - CoA dehydrogenase (MCAD) deficiency, short - chain acyl- CoA dehydrogenase (SCAD) deficiency, and riboflavin - responsive disorders of β -oxidation (RR -MADD).

In some embodiments, the PPAR δ -related disease is a vascular disease. Examples of vascular diseases include, but are not limited to, peripheral vascular insufficiency, peripheral vascular disease, intermittent claudication, peripheral vascular disease (PVD), peripheral artery disease (PAD), peripheral artery occlusive disease (PAOD), and peripheral obliterative arteriopathy.

In other embodiments, the PPAR δ -related disease is an ocular vascular disease. Examples of ocular vascular diseases include, but are not limited to, age-related macular degeneration (AMD), stargardt disease, hypertensive retinopathy, diabetic retinopathy, retinopathy, macular degeneration, retinal haemorrhage, and glaucoma.

In yet other embodiments, the PPAR δ -related disease is a muscular eye disease. Examples of muscular eye diseases include, but are not limited to, strabismus (crossed

eye/wandering eye/walleye ophthalmoparesis), progressive external ophthalmoplegia, esotropia, exotropia, a disorder of refraction and accommodation, hypermetropia, myopia, astigmatism, anisometropia, presbyopia, a disorders of accommodation, or internal ophthalmoplegia.

5 In yet other embodiments, the PPAR δ -related disease is a metabolic disease. Examples of metabolic disorders include, but are not limited to, hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, HDL hypocholesterolemia, LDL hypercholesterolemia and/or HLD non-cholesterolemia, VLDL hyperproteinemia, dyslipoproteinemia, apolipoprotein A-I hypoproteinemia, atherosclerosis, disease of arterial
10 sclerosis, disease of cardiovascular systems, cerebrovascular disease, peripheral circulatory disease, metabolic syndrome, syndrome X, obesity, diabetes (type I or II), hyperglycemia, insulin resistance, impaired glucose tolerance, hyperinsulinism, diabetic complication, cardiac insufficiency, cardiac infarction, cardiomyopathy, hypertension, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), thrombus, Alzheimer disease,
15 neurodegenerative disease, demyelinating disease, multiple sclerosis, adrenal leukodystrophy, dermatitis, psoriasis, acne, skin aging, trichosis, inflammation, arthritis, asthma, hypersensitive intestine syndrome, ulcerative colitis, Crohn's disease, and pancreatitis.

 In still other embodiments, the PPAR δ -related disease is cancer. Examples of cancer include, but are not limited to, cancers of the colon, large intestine, skin, breast, prostate,
20 ovary, and/or lung.

 In other embodiments, the PPAR δ -related disease is a renal disease. Examples of renal diseases include, but are not limited to, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury
25 (also known as acute renal failure), chronic renal failure, diabetic nephropathy, or Bartter's syndrome. PCT/US2014/033088, incorporated herein by reference, demonstrates genetic and pharmacological activation of PPAR δ promotes muscle regeneration in an acute thermal injury mouse model. Accordingly, use of PPAR δ as a therapeutic target to enhance regenerative efficiency of skeletal muscle is also provided.

30

Pharmaceutical Compositions and Administration Thereof

 The precise amount of compound administered to provide a "therapeutically effective amount" to the subject will depend on the mode of administration, the type, and severity of

the disease, and on the characteristics of the subject, such as general health, age, sex, body weight, and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The term “therapeutically effective amount” means an amount when administered to the subject which results in beneficial or desired results, including clinical results, *e.g.*, inhibits, suppresses or reduces the symptoms of the condition being treated in the subject as compared to a control. For example, a therapeutically effective amount can be from, *e.g.*, 0.1 mg to about 50 g per day.

The terms “administer”, “administering”, “administration”, and the like, as used herein, refer to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like. Oral and intravenous administration are commonly used, for example, when the condition being treated is acute kidney injury. Administration techniques that can be employed with the agents and methods described herein are found in *e.g.*, Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, current ed.; Pergamon; and Remington’s, *Pharmaceutical Sciences* (current edition), Mack Publishing Co., Easton, Pa.

Pharmaceutical compositions are disclosed that include the salts of Compound A and/or Compound B, and typically at least one additional substance, such as an excipient, a known therapeutic other than those of the present disclosure, and combinations thereof.

The pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. In an embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings.

Administration of therapeutic agents by intravenous formulation is well known in the pharmaceutical industry. Intravenous formulations comprise the pharmaceutically active agent dissolved in a pharmaceutically acceptable solvent or solution, such as sterile water, normal saline solutions, lactated Ringer’s, or other salt solutions such as Ringer’s solution.

For example, the formulation should promote the overall stability of the active ingredient(s), also, the manufacture of the formulation should be cost-effective. All of these factors ultimately determine the overall success and usefulness of an intravenous formulation.

An oral formulation typically is prepared as a compressed preparation in, for example, the form of a tablet or pill. A tablet may contain, for example, about 5–10% of the active ingredient (*e.g.*, a salt of Compound A or B); about 80% of fillers, disintegrants, lubricants,

glidants, and binders; and 10% of compounds which ensure easy disintegration, disaggregation, and dissolution of the tablet in the stomach or the intestine. Pills can be coated with sugar, varnish, or wax to disguise the taste.

5

EXEMPLIFICATION

*Example 1***PPAR δ activity screen**

Cell Culture and Transfection: CV-1 cells were grown in DMEM+10% charcoal stripped FCS. Cells were seeded into 384-well plates the day before transfection to give a confluency of 50-80% at transfection. A total of 0.8 g DNA containing 0.64 micrograms pCMX-PPARDelta LBD, 0.1 micrograms pCMX.beta.Gal, 0.08 micrograms pGLMH2004 reporter and 0.02 micrograms pCMX empty vector was transfected per well using FuGene transfection reagent according to the manufacturer's instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound.

Plasmids: Human PPAR δ was used to PCR amplify the PPAR δ LBD. The amplified cDNA ligand binding domain (LBD) of PPAR δ isoform was (PPAR δ amino acid 128 to C-terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by subcloning fragments in frame into the vector pCMX GAL (Sadowski *et al.* (1992), Gene 118, 137) generating the plasmids pCMX-PPARDelta LBD. Ensuing fusions were verified by sequencing. The pCMXMH2004 luciferase reporter contains multiple copies of the GAL4 DNA response element under a minimal eukaryotic promoter (Hollenberg and Evans, 1988). pCMX β Gal was generated.



Compounds: All compounds were dissolved in DMSO and diluted 1:1000 upon addition to the cells. Compounds were tested in quadruple in concentrations ranging from 0.001 to 100 μ M. Cells were treated with compound for 24 h followed by luciferase assay. Each compound was tested in at least two separate experiments.

Luciferase assay: Medium including test compound was aspirated and washed with PBS. 50 μ l PBS including 1 mM Mg $^{++}$ and Ca $^{++}$ were then added to each well. The luciferase assay was performed using the LucLite kit according to the manufacturer's instructions (Packard Instruments). Light emission was quantified by counting on a Perkin Elmer Envision reader. To measure 3-galactosidase activity 25 μ l supernatant from each transfection lysate was transferred to a new 384 microplate. Beta-galactosidase assays were performed in the microwell plates using a kit from Promega and read in a Perkin Elmer

Envision reader. The beta-galactosidase data were used to normalize (transfection efficiency, cell growth etc.) the luciferase data.

Statistical Methods: The activity of a compound is calculated as fold induction compared to an untreated sample. For each compound the efficacy (maximal activity) is given as a relative activity compared to GW501516, a PPAR δ agonist. The EC₅₀ is the concentration giving 50% of maximal observed activity. EC₅₀ values were calculated via non-linear regression using GraphPad PRISM (GraphPad Software, San Diego, Calif.).

Table 1. PPARdelta Activity Screen

Compound	Structure	Mol.Wt	PPAR delta transactivation EC50 (nM)
<i>Compound A</i>		460.41	0.10
<i>Compound B</i>		461.49	4.40

The compounds of this invention show a good agonistic activity of PPAR δ , a good selectivity of PPAR δ , a good pharmacological effect, good PK profiles and/or low toxicity including CYP inhibition and hERG inhibition.

Example 2

Synthetic Preparation of Compounds A and B

Abbreviations

Me methyl

Et ethyl

nPr *n*-propyl

iPr isopropyl


cPr cyclopropyl

nBu *n*-butyl


	iBu	isobutyl
	tBu	<i>tert</i> -butyl
	Boc	<i>tert</i> -butoxycarbonyl
	Ac	acetyl
5	Ph	phenyl
	Tf	trifluoromethanesulfonyl
	Ts	4-methylphenylsulfonyl
	DIAD	diisopropyl azodicarboxylate
	EDCI	3-(3-dimethylaminopropyl)-1-ethylcarbodiimide
10	HOBt	1-hydroxybenzotriazole
	HATU	1-[bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- <i>b</i>]pyridinium 3-oxide hexafluorophosphate
	HBTU	<i>N,N,N',N'</i> -Tetramethyl-O-(1 <i>H</i> -benzotriazol-1-yl)uronium hexafluorophosphate
15	NBS	N-bromosuccinimide
	DIPEA	diisopropylethylamine
	mCPBA	m-chloroperoxybenzoic acid
	Togni's reagent	3,3-dimethyl-1-(trifluoromethyl)-1,2-benziodoxole
	DCM	dichloromethane
20	DME	dimethoxyethane
	DMF	<i>N,N</i> -dimethylformamide
	DMF.DMA	<i>N,N</i> -dimethylformamide dimethyl acetal
	DMSO	dimethylsulfoxide
	TFA	trifluoroacetic acid
25	THF	tetrahydrofuran
	MW	microwave irradiation
	aq	Aqueous
	M	concentration expressed in mol/L
	RT	room temperature
30	TLC	thin layer chromatography
	HPLC	high-performance liquid chromatography
	MPLC	medium pressure liquid chromatography
	LCMS	liquid chromatography-mass spectrometry
	ESI+	Electrospray ionization positive mode


ESI-	Electrospray ionization negative mode
^1H NMR (DMSO- d_6) δ (ppm) of peak in ^1H NMR in DMSO- d_6	
s	singlet (spectrum)
d	doublet (spectrum)
5 t	triplet (spectrum)
q	quartet (spectrum)
dd	double doublet (spectrum)
br	broad line (spectrum)
m	multiplet (spectrum)

Example 2a: Synthesis of (*R*)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1*H*-imidazol-1-yl)methyl)phenoxy)hexanoic acid (*Compound A*)




Scheme:



Synthesis of ethyl (R)-6-bromo-3-methylhexanoate:

In a 1 L round bottom flask, a solution of ethyl (R)-6-hydroxy-3-methylhexanoate (65.0 g, 373.56 mmol) in DCM (650 mL) was treated with PBr₃ (101.0 g, 373.56 mmol) at RT. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (3 x 500 mL). The organic extract was separated and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to get the title compound (57.12 g).


10 *Step-1: Synthesis of N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide:*



In a 500 mL round bottom flask, a stirred solution of 4-(trifluoromethyl)benzoic acid (10 g, 52.63 mmol) and prop-2-yn-1-amine (3.47 g, 63.15 mmol) in DMF (200 mL) was treated sequentially with EDCI.HCl (20.09 g, 105.2 mmol), HOBt (14.2 g, 105.2 mmol) and Et₃N (14.6 mL, 105.2 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice cold water and solid precipitated out. The solid was filtered and dried under reduced pressure to yield the title compound (8.42 g, 70.5%).

20 ¹H NMR (300 MHz, CDCl₃): δ 7.90 (d, *J* = 8.1 Hz, 2H), 7.71 (d, *J* = 8.8 Hz, 2H), 6.47 (brs, 1H), 4.28-4.62 (m, 2H), 3.12 (t, *J* = 2.4 Hz, 1H). LCMS (ESI+, *m/z*): 228.2 (M+H)⁺.

Step-2: Synthesis of 1-(2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazole:




25

In a 500 mL resealable reaction tube, a solution of N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide (13.3 g, 58.59 mmol) and 2-methoxybenzyl amine (12.0 g, 87.84 mmol) in toluene (150 mL) was treated with Zn(OTf)₂ (6.67 g, 17.5 mmol) at RT under nitrogen atmosphere. The reaction mixture was heated at 110°C for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (3 x 100 mL). The combined organic extract was washed with saturated NaHCO₃, brine and dried over anhydrous Na₂SO₄. The solution was concentrated under reduced pressure and the residue obtained was purified by silica gel column chromatography (elution, 25% EtOAc in hexanes) to afford the title compound (17.3 g, 85.3%).

¹H NMR (400 MHz, CDCl₃): δ 7.59-7.54 (m, 4H), 7.30-7.23 (m, 1H), 7.00 (s, 1H), 6.91-6.86 (m, 2H), 6.57 (d, *J* = 7.2 Hz, 1H), 5.11 (s, 2H), 3.84 (s, 3H), 2.11 (s, 3H). LCMS (ESI+, *m/z*): 347.3 (M+H)⁺.


Step-3: Synthesis of 2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenol:



In a 500 mL round bottom flask, a solution of 1-(2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazole (17.3 g, 49.94 mmol) in DCM (150 mL) was treated with BBr₃ (1.0 M, 90.0 mL) drop wise at 0°C. The reaction mixture was stirred at RT for 4 h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified (pH ~ 9) with aqueous NaHCO₃ and extracted with EtOAc (3 x 500 mL). The combined organic extract was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (19.2 g, crude).


¹H NMR (400 MHz, DMSO-d₆): δ 9.99 (s, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.77 (d, *J* = 8.4 Hz, 2H), 7.33 (s, 1H), 7.14-7.10 (m, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.74-6.70 (m, 1H), 6.55 (d, *J* = 6.8 Hz, 1H), 5.21 (s, 2H), 2.16 (s, 3H). LCMS (ESI+, *m/z*): 333.3 (M+H)⁺.

Step-4: Synthesis of ethyl (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate:



In a 250 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(4-(trifluoromethyl) phenyl)-1H-imidazol-1-yl)methyl)phenol (4.0 g, 12.0 mmol) in DMF (100 mL) was treated with KO^tBu (4.03 g, 36.1 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (8.52 g, 36.10 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 12 h. Upon completion of the reaction (monitored by TLC), the reaction mixture quenched with ice cold water and extracted with EtOAc (3 x 100 mL). The combined organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (3.31 g, 56.3%). LCMS (ESI+, *m/z*): 489.3 (M+H)⁺.

Step-5: Synthesis of (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound A):




In a 250 mL round bottom flask, a stirred solution of ethyl (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (3.3 g, 6.75 mmol) in THF (30 mL), ethanol (10 mL) and water (10 mL) was treated with lithium hydroxide monohydrate (1.42 g, 33.8 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The residue obtained was washed with EtOAc, diluted


with cold water and acidified (pH ~5) with 1N HCl. The solid obtained was filtered and dried under reduced pressure to give the title compound (1.12 g, 36.0 %).

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (brs, 1H), 7.71 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.26-7.21 (m, 1H), 7.01 (d, *J* = 8.4 Hz, 1H), 6.93 (s, 1H), 6.86-6.83 (m, 1H), 6.38 (d, *J* = 6.8 Hz, 1H), 5.16 (s, 2H), 3.98 (t, *J* = 6.0 Hz, 2H), 2.19-2.14 (m, 1H), 2.08 (s, 3H), 1.99-1.93 (m, 1H), 1.84-1.76 (m, 1H), 1.67-1.65 (m, 2H), 1.45-1.42 (m, 1H), 1.28-1.18 (m, 1H), 0.83 (d, *J* = 6.4 Hz, 3H). ¹⁹F NMR (400 MHz, DMSO-d₆): δ -56.4. LCMS (ESI+, *m/z*): 460.8 (M+H)⁺. HPLC: 98.89 % (210 nm).


10 **Example 2b: Synthesis of (*R*)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1*H*-imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound B).**



Scheme:



Step-1: Synthesis of *N*-(prop-2-yn-1-yl)-6-(trifluoromethyl)nicotinamide:




In a 100 mL round bottom flask, a stirred solution of 6-(trifluoromethyl)nicotinic acid (3 g, 15.70 mmol) and prop-2-yn-1-amine (1.05 g, 18.84 mmol) in DMF (50 mL) was treated with HATU (7.2 g, 18.84 mmol) and Et₃N (3.1 mL, 23.55 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with cold water and solid precipitated was filtered, washed with water and dried under reduced pressure to get the title compound (2.6 g, 72.6 %).

¹H NMR (300 MHz, CDCl₃): δ 9.08 (d, *J* = 2.1 Hz, 1H), 8.32 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.78 (d, *J* = 7.8 Hz, 1H), 6.62 (brs, 1H), 4.30-4.28 (m, 2H), 2.33 (t, *J* = 2.4 Hz, 1H).

LCMS (ESI+, *m/z*): 229.2 (M+H)⁺.


Step-2: Synthesis of 5-(1-(2-methoxybenzyl)-5-methyl-1*H*-imidazol-2-yl)-2-(trifluoromethyl)pyridine:



In a 50 mL resealable tube, a solution of *N*-(prop-2-yn-1-yl)-6-(trifluoromethyl)nicotinamide (1.0 g, 4.38 mmol) and 2-methoxyphenylbenzyl amine (1.2 g, 8.77 mmol) in toluene (10 mL) was treated with Zn(OTf)₂ (0.16 g, 0.43 mmol) at RT under nitrogen atmosphere. The reaction mixture was heated at 120°C for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (3 x 20 mL). The organic extract was washed with saturated NaHCO₃, brine and dried over anhydrous Na₂SO₄. The solution was concentrated under reduced pressure and residue obtained was purified by silica gel column chromatography (elution, 25% EtOAc in hexanes) to yield the title compound (0.8 g, 52.6%).

¹H NMR (400 MHz, CDCl₃): δ 8.79 (s, 1H), 8.07 (d, *J* = 8.1 Hz, 1H), 7.68 (d, *J* = 8.1 Hz, 1H), 7.31 (t, *J* = 8.4 Hz, 1H), 7.09 (s, 1H), 6.94-6.87 (m, 2H), 6.56 (d, *J* = 7.5 Hz, 1H), 5.16 (s, 2H), 3.87 (s, 3H). LCMS (ESI+, *m/z*): 348.3 (M+H)⁺.


5 *Step-3: Synthesis of 2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenol:*



In a 100 mL round bottom flask, a solution of 5-(1-(2-methoxybenzyl)-5-methyl-1H-imidazol-2-yl)-2-(trifluoromethyl)pyridine (0.8 g, 2.31 mmol) in dichloromethane (300 mL) was treated with BBr₃ (0.8 mL, 2.31 mmol) drop wise at 0°C. The reaction mixture was stirred at RT for 2 h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified (pH ~ 9) with aqueous NaHCO₃ and extracted with EtOAc. The organic extract was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (0.5 g, 65.1%)

15 ¹H NMR (400 MHz, DMSO-d₆): δ 9.92 (s, 1H), 8.83 (s, 1H), 8.12 (d, *J* = 8.1 Hz, 1H), 7.94 (d, *J* = 8.1 Hz, 1H), 7.12 (d, *J* = 6.9 Hz, 1H), 7.02 (s, 1H), 6.87 (d, *J* = 7.8 Hz 1H), 6.73 (t, *J* = 7.2 Hz, 1H), 6.37 (d, *J* = 7.2 Hz, 1H), 5.20 (s, 2H), 2.15 (s, 3H). LCMS (ESI+, *m/z*): 334.3 (M+H)⁺.

20 *Step-4: Synthesis of ethyl (R)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate:*




In a 50 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenol (0.5 g, 1.50 mmol) (a procedure for the preparation of which is disclosed in U.S. Application No. 62/061,483,

incorporated herein by reference) in DMF (10 mL) was treated with K_2CO_3 (0.41 g, 3.00 mmol) and ethyl (*R*)-6-bromo-3-methylhexanoate (0.710 g, 3.00 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was heated 60°C for 12 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and
 5 extracted with ethyl acetate (75 mL X 3). The combined organic extract was washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (0.45 g, 61.3%).

LCMS (ESI+, m/z): 491.0 ($M+H$)⁺.

10

Step-5: Synthesis of (R)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound B):



In a 250 mL round bottom flask, a stirred solution of ethyl (*R*)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.45 g, 0.92 mmol) in THF (5 mL), ethanol (2.5 mL) and water (2.5 mL) was treated with lithium hydroxide monohydrate (16.0 g, 74.33 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The residue obtained was washed with
 15 EtOAc, diluted with cold water and acidified (pH ~5) with 1N HCl. The solid was filtered and dried under reduced pressure to give the title compound (0.166 g, 39.2 %).

¹H NMR (400 MHz, DMSO- d_6): δ 11.96 (brs, 1H), 8.79 (s, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 7.00 (s, 1H), 6.84 (t, J = 7.6 Hz, 1H), 6.43 (d, J = 7.2 Hz, 1H), 5.21 (s, 2H), 3.98 (t, J = 6.0 Hz, 2H), 2.19-2.14 (m, 1H), 2.13 (s, 3H), 2.03-1.94 (m, 1H), 1.85-1.80 (m, 1H), 1.68-1.66 (m, 2H), 1.38-1.36 (m, 1H), 1.28-1.18 (m, 1H), 0.85 (d, J = 6.4 Hz, 3H). ¹⁹F NMR (400 MHz, DMSO- d_6): δ -66.46.
 25 LCMS (ESI+, m/z): 462.3 ($M+H$)⁺. HPLC: 95.11 % (210 nm).

Example 3**Compound A Salt Screen**

A 25 mg/mL stock solution of Compound A was prepared in methanol. Then, 2 mL of Compound A stock solution was dispensed into 4 mL amber glass vials. Salt formers (1 eq) were then added to the vials as listed in Table 1 and the solvents were removed by evaporation under a stream of nitrogen. Once evaporation was completed, the screening solvents listed in Table 1 were pipetted in, the vials were sealed, and the samples were put onto a 50 °C stir plate to stir for up to an hour. Then, the heat was shut off and samples were allowed to cool to 25 °C with stirring. Experiments resulting in slurries were stirred.

Experiments resulting in solutions were converted to evaporative crystallizations.

Solids isolated from the experiments were characterized by XRPD to determine if they were crystalline as well as unique solid state forms suggesting salt formation occurred.

An additional experiment was performed with the suspected sodium salt in an attempt to create a Compound A sodium salt. The suspected sodium salt isolated from acetonitrile was slurried in ethyl acetate for six days at 25 °C. Solids were analyzed by XRPD, which showed a physical mixture of Compound A free form and the starting suspected sodium salt isolated from acetonitrile. No new salt form was generated.

Table 1. Salt Screening Experiments for Compound A

Sample	Salt Former	Solvent	Temperature	Results
1	HCl	2-Propanol	25 °C	Gel
2	H ₂ SO ₄	2-Propanol	25 °C	New Salt Form A (Hemisulfate Form 1)
3	H ₃ PO ₄	2-Propanol	25 °C	New Salt Form B
4	p-Toluenesulfonic Acid	2-Propanol	25 °C	Gel
5	Methanesulfonic Acid	2-Propanol	25 °C	Gel
6	NaOH	2-Propanol	25 °C	New Salt Form C
7	KOH	2-Propanol	25 °C	Gel
8	Choline Hydroxide	2-Propanol	25 °C	New Salt Form D
9	L-Arginine	2-Propanol	25 °C	Amorphous
10	L-Lysine	2-Propanol	25 °C	New Salt Form E
11	N-Methyl-D-Glucamine	2-Propanol	25 °C	Gel
12	TRIS	2-Propanol	25 °C	New Salt Form F
13	HCl	Acetonitrile	25 °C	Gel

Sample	Salt Former	Solvent	Temperature	Results
14	H ₂ SO ₄	Acetonitrile	4 °C	New Salt Form A (Hemisulfate Form 1)
15	H ₃ PO ₄	Acetonitrile	25 °C	New Salt Form B
16	p-Toluenesulfonic Acid	Acetonitrile	25 °C	Gel
17	Methanesulfonic Acid	Acetonitrile	25 °C	Gel
18	NaOH	Acetonitrile	25 °C	New Salt Form C
19	KOH	Acetonitrile	25 °C	Semi-Crystalline
20	Choline Hydroxide	Acetonitrile	25 °C	New Salt Form D
21	L-Arginine	Acetonitrile	25 °C	Amorphous
22	L-Lysine	Acetonitrile	25 °C	New Salt Form E
23	N-Methyl-D-Glucamine	Acetonitrile	25 °C	Mixture of Starting Material
24	TRIS	Acetonitrile	4 °C	Starting Material

Example 4

Stability of Compound A Salts

The stability of the sulfate, phosphate, L-lysine, and TRIS salts prepared in Example 3 were tested. Approximately 20 mg of each sample was combined with 1 mL of water in microcentrifuge tubes. The samples were allowed to mix overnight on a temperature controlled shaker at 20 °C at 850 rpm. The solids were characterized by XPRD to determine if a solid state form change occurred. There was no change in the solids for the suspected sulfate salt as well as the starting material. However, the suspected phosphate, L-lysine, and TRIS salts appear to disproportionate back to the starting material in aqueous environments.

Example 5

Preparation of Compound A Hemisulfate Form 1

In a 50 mL vial was dissolved 883.2 mg of Compound A was dissolved in 35 mL methanol. Then, H₂SO₄ (1920 µL, 1M in H₂O, 1 equivalent) was pipetted in. The solvent was allowed to evaporate under N₂. Once evaporated, 2-propanol (18 mL) was pipetted in followed by a stir bar. The vial was capped and placed on a 50°C stir plate for 1 hour, then the temperature was dropped to 25°C, where it stirred for 1 day. After 1 day, the solids were filtered under vacuum and allowed to air dry.

¹H NMR (400 MHz, DMSO-d₆): δ 7.85 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.36 (s, 1H), 7.27 (t, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 6.85 (t, *J* = 7.6 Hz, 1H), 6.62 (d, *J* = 7.2 Hz, 1H), 5.26 (s, 2H), 3.96 (t, *J* = 6.0 Hz, 2H), 2.21-2.16 (m, 4H), 1.96 (dd, *J* = 8.0, 15.2 Hz, 1H), 1.83-1.80 (m, 1H), 1.67-1.59 (m, 2H), 1.35-1.31 (m, 1H), 1.28-1.18 (m, 1H), 0.85 (d, *J* = 6.4 Hz, 3H).

Mass Spectrum (ESI) *m/e* 461.2.

Elemental Analysis: Calculated: C 58.93%; H 5.54%; N 5.50%; S 3.15. Observed: C 58.30%; H 5.36%; N 5.42%; S 3.47.

The Compound A hemisulfate form 1 was also obtained according to the same manner as that mentioned above using acetonitrile (18 mL) as a solvent instead of 2-propanol (18 mL).

The elemental analysis of Compound A hemisulfate form 1 shows that it contains a two to one ratio of Compound A cation to sulfate anion.

The presence of the sulfate anion as well as the sulfate stoichiometry was confirmed through elemental analysis, which revealed two molecules of Compound A to one molecule of sulfate anion.

The sulfate salt was named Compound A hemisulfate form 1. This form was subjected to a thermodynamic stability form screen to see if a more stable form could be identified as well as screen for solvates, hydrates, and assess the risk of disproportionation (Example 7). Chemical and physical stability data as well as hygroscopicity data were also generated for Compound A hemisulfate form 1 (Example 11).

Example 6

Compound A Hemisulfate Form 1 Characterization

Physical characterization consisting of XRPD (FIG. 1), TGA, and DSC was performed for Compound A hemisulfate form 1. A summary of the XRPD data from FIG. 1 for Compound A hemisulfate Form 1 is provided in Table 3.

Table 3.

Number	Position [°2θ]	d-spacing [Å]	Height [cts]
1	7.2723	12.15596	203.49
2	8.3321	10.61206	87.18

Number	Position [$^{\circ}2\theta$]	d-spacing [$\text{\AA}$]	Height [cts]
3	12.9823	6.81943	34.79
4	14.682	6.03356	187.57
5	15.7717	5.61908	68.85
6	16.5492	5.35679	72.4
7	17.3066	5.12403	36.33
8	19.1525	4.63415	149.22
9	19.6624	4.51512	80.9
10	20.7187	4.28724	15.2
11	22.268	3.99234	224.73
12	23.8209	3.73547	49.9
13	24.5362	3.62817	37.27
14	24.9107	3.57448	34.45
15	25.7712	3.45704	95.31
16	26.2777	3.39155	39.15
17	27.8254	3.20632	40.71
18	28.5033	3.13158	16
19	29.5617	3.02183	16.5
20	33.7206	2.65804	3.18

X-ray powder diffraction data were collected under ambient conditions on a Rigaku Miniflex 600 diffractometer using Cu K alpha (1.5406 Angstrom) radiation. Powder patterns were collected on a zero background holder with a 0.1 mm indent at a scan rate of 2 to 40° two theta at 2° per min at 40 kV and 15 mA. Data was analyzed using High Score Plus version 4.1.

5

*Example 7***Compound A Hemisulfate Form Screening**

A thermodynamic stability form screen was initiated with Compound A hemisulfate form 1 to screen for thermodynamically more stable polymorphs, solvates, and hydrates as well as to probe the tendency to disproportionate back to Compound A. Approximately 90 to 110 mg of Compound A hemisulfate form 1 was weighed out and transferred into 4 mL amber glass vials followed by 0.8 to 1 mL of solvent and a magnetic stir bar. The vials were sealed then placed onto temperature controlled stir plates and stirred for fifteen days at 500 rpm. Solvents and temperatures are listed in Table 4. XRPD analyses of the solids revealed no change in solid state form occurred except for the solids isolated from experiments in methanol at 25 °C and water/methanol at 25 °C. This new form is different than the starting Compound A free form and Compound A hemisulfate form 1.

Table 4. Compound A Hemisulfate Slurry Screen

Experiment	Solvent	Temperature	Results
1	Ethyl Acetate	50 °C	No change in form
2	2-Propanol	50 °C	No change in form
3	Acetone	25 °C	No change in form
4	Dichloromethane	4 °C	No change in form
5	Acetonitrile	50 °C	No change in form
6	Tetrahydrofuran	25 °C	No change in form
7	Water	25 °C	No change in form
8	Water/Methanol (1/3, v/v)	25 °C	Compound A Hemisulfate Form 2
9	Water/Acetonitrile (1/3, v/v)	4 °C	No change in form
10	Ethanol	50 °C	No change in form
11	2-Methyl-THF	25 °C	No change in form
12	CPME	50 °C	No change in form

Experiment	Solvent	Temperature	Results
13	Toluene	50 °C	No change in form
14	Methanol	25 °C	Compound A Hemisulfate Form 2

Example 8

Compound A Hemisulfate Form 2 Characterization

The new solid state form isolated from the methanol slurry and water/methanol slurry in Example 7 was subjected to additional characterization and found to be a new polymorph of the hemisulfate salt of Compound A. This new form was named Compound A hemisulfate form 2. Physical characterization consisting of XRPD (FIG. 2), TGA and DSC was performed for Compound A hemisulfate form 2 after drying under nitrogen. A summary of the XRPD data from FIG. 2 for Compound A hemisulfate form 2 is provided in Table 5.

Table 5.

Number	Position [°2θ]	d-spacing [Å]	Height [cts]
1	6.6699	13.25246	565.65
2	10.0501	8.80157	17.65
3	11.077	7.98776	17.71
4	13.5016	6.55831	54.27
5	14.2386	6.22046	23.63
6	14.5068	6.10605	44.53
7	14.8445	5.96788	22.89
8	16.0872	5.50958	33.53
9	16.9192	5.24047	17.12
10	17.4339	5.08691	84.25
11	18.0914	4.90349	288.69
12	18.975	4.67709	26.04

Number	Position [$^{\circ}2\theta$]	d-spacing [$\text{\AA}$]	Height [cts]
13	19.899	4.46195	12.96
14	22.3828	3.97212	48.96
15	23.2046	3.83327	41.82
16	23.4233	3.79797	44.01
17	25.0416	3.55607	29.72
18	26.7503	3.33269	20.02
19	27.3864	3.2567	20.05
20	29.3568	3.04246	9.17

X-ray powder diffraction data were collected under ambient conditions on a Rigaku Miniflex 600 diffractometer using Cu K alpha (1.5406 Angstrom) radiation. Powder patterns were collected on a zero background holder with a 0.1 mm indent at a scan rate of 2 to 40° two theta at 2° per min at 40 kV and 15 mA. Data was analyzed using High Score Plus version 4.1.

Solution ^1H NMR and elemental analysis data were also generated to check for chemical changes, as compared against the free base and initial hemisulfate form 1. The data indicate no molecular transformation occurred and that Compound A hemisulfate form 2 is not a solvate. Also, the solution ^1H NMR and elemental analysis data were consistent with the material being a hemisulfate salt having a two to one ration of Compound A cation to sulfate anion.

Example 9

Relative Thermodynamic Stability of Compound A Hemisulfate Form 1 and Form 2

The relative thermodynamic stability of Compound A hemisulfate form 1 and hemisulfate form 2 was determined through a comparison of thermal analysis data for each form as well as competition slurry experiments. DSC data for Compound A hemisulfate form 1 revealed this form has an onset melting point of 185.7 °C and an enthalpy of fusion of 106.9 joules per gram. DSC data for Compound A hemisulfate form 2 revealed this form has an onset melting point of 177.4 °C and an enthalpy of fusion of 98.9 joules per gram. According to the heat of fusion rule, Compound A hemisulfate form 1 and hemisulfate form 2

are monotropically related given Compound A hemisulfate form 1 has the higher melting point and the higher enthalpy of fusion of the two polymorphs. Compound A hemisulfate form 1 is the thermodynamically more stable form.

Competition slurry experiments were conducted to confirm the relative thermodynamic stabilities of Compound A hemisulfate form 1 and Compound A hemisulfate form 2. Mixtures of both forms were slurried together in 0.5 mL acetone at 25 °C for one week. Both forms were still present in the slurry, so the experiment was moved to 4 °C. After ten days at 4 °C, XRPD analysis showed that the mixture converted to Compound A hemisulfate form 1, indicating Compound A hemisulfate form 1 is more stable than Compound A hemisulfate form 2 at 4 °C.

Compound A hemisulfate form 1 and Compound A hemisulfate form 2 were slurried together in 0.5 mL acetonitrile at 50 °C. After three days at 50 °C, XRPD analysis showed both forms still remaining in the slurry. After ten days at 50 °C in acetonitrile, XRPD analysis showed that the mixture converted to Compound A hemisulfate form 1, indicating the Compound A hemisulfate form 1 is more thermodynamically stable than Compound A hemisulfate form 2 at 50 °C.

Compound A hemisulfate form 1 and Compound A hemisulfate form 2 were slurried together in 0.5 mL ethyl acetate at 25 °C. After two days, both forms were still present in the slurry, so the experiment was moved to 4 °C. After eight days at 4 °C, XRPD analysis showed that the solids remained a mixture of forms. This experiment was stopped before fully converting to a single form given mixtures converted to Compound A hemisulfate form 1 in acetone at 4 °C and in acetonitrile at 50 °C. This experiment demonstrates the conversion from Compound A hemisulfate form 2 to Compound A hemisulfate form 1 can be slow under certain conditions.

Both thermal analysis data and competition slurry experiment data demonstrate Compound A hemisulfate form 1 is thermodynamically more stable than Compound A hemisulfate form 2. Methanol was always present in the solvent system when Compound A hemisulfate form 2 was formed which suggests Compound A hemisulfate form 2 might be formed through the desolvation of an unstable and never observed methanol solvate.

Example 10

Compound A Hemisulfate Form 1 Stability and Hygroscopicity

An eight week chemical and physical stability study was conducted for Compound A hemisulfate form 1. The material was stored at 4 °C, 25 °C /60% RH, 40 °C, and 40 °C /75%

RH for eight weeks as well as stressed conditions of 70 °C and 70 °C /75% RH for two weeks. In addition, photostability was also measured after exposing the material to two cycles of ICH conditions. Degradation and recovery was measured by HPLC. See Table 6 for HPLC results, including percent recovery of solids and relative retention time area percentages, compared against the standard stored at 4 °C.

Table 6. Summary of HPLC data.

Sample	%	RRT	*RRT	RRT	RRT	RRT	RRT	RRT
4°C, 4wk	101	1.16	0.21	97.36	0.21	0.20	0.25	0.58
4°C, 8 wk	100	1.15	0.12	97.42	0.34	0.19	0.24	0.54
25°C/60% RH, 4 wk	100	1.20	0.21	97.40	0.21	0.21	0.25	0.50
25°C/60% RH, 8wk	99	1.15	0.04	97.67	0.25	0.19	0.23	0.46
40°C, 4 wk	101	1.20	0.22	97.27	0.21	0.20	0.25	0.59
40°C, 8wk	101	1.16	0.11	97.44	0.33	0.19	0.24	0.53
40°C/75% RH, 4 wk	101	1.24	0.21	97.33	0.21	0.21	0.25	0.50
40°C/75% RH, 8wk	100	1.19	0.04	97.63	0.30	0.19	0.23	0.42
70°C, 2 wk	101	1.20	0.18	97.34	0.22	0.21	0.26	0.55
70°C/75% RH, 2 wk	101	1.22	0.19	97.45	0.22	0.21	0.24	0.42
Photo	98	1.11	0.10	97.78	0.27	0.20	0.14	0.40
Control (dark)	100	1.16	0.07	97.53	0.30	0.19	0.23	0.53
Standard	N/A	1.18	0.14	97.38	0.37	0.18	0.23	0.53

XRPD was used to check the physical stability. No changes in solid state form were observed in all conditions.

Dynamic vapor sorption analysis was performed on Compound A hemisulfate form 1 at 25 °C. At approximately 90% RH, the material reversibly picks up approximately 3.5% water by weight. After DVS was completed, the solid collected was checked by XRPD, which showed that the material remained Compound A hemisulfate form 1.

Example 11

Preparation of Meglumine Salt of Compound B

Two separate methods were used to generate a meglumine salt of Compound B.

Method 1

Compound B (102.7 mg) was combined with meglumine (43.7 mg) and 2 mL of 2-propanol in a 4 mL glass vial. The vial was sealed with a cap and the contents were subjected to sonication at 25 °C for 20 minutes followed by stirring at 50 °C for 60 minutes. The vial was then moved to a new stir plate and the slurry in the vial was stirred at 25 °C.

Method 2

Compound B (102.2 mg) was combined with meglumine (43.2 mg) and 2 mL of acetonitrile in a 4 mL glass vial. The vial was sealed with a cap and the contents were subjected to sonication at 25 °C for 20 minutes followed by stirring at 50 °C for 60 minutes.

- 5 The vial was then moved to a new stir plate and the slurry in the vial was stirred at 25 °C.

For both method 1 and method 2, after 2 days of stirring at 25 °C, both samples were centrifuged, supernatants discarded, and solids were air dried.

10

*Example 12***Preparation of Hydrate of Meglumine Salt of Compound B**

In a 500 mL round bottom flask, a stirred solution of Compound B (20 g, 43.33 mmol) in THF (100 mL) and water (100 mL) was treated meglumine (8.45 g, 43.33 mmol) at 0°C. The resulting reaction mixture was stirred at RT for 6 h. The reaction mixture was concentrated under reduced pressure and solid obtained was dried under reduced pressure (3h) to afford the title compound as a white solid (28.5 g, 98.95%).

- 15 ¹H NMR (400 MHz, CD₃OD): δ 8.75 (s, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.26 (t, *J* = 8.4 Hz, 1H), 7.03 (s, 1H), 6.99 (d, *J* = 8 Hz, 1H), 6.85 (t, *J* = 7.6 Hz, 1H), 6.50 (d, *J* = 7.6 Hz, 1H), 5.25 (s, 2H), 4.09-3.99 (m, 3H), 3.97-3.77 (m, 2H), 3.74-3.61 (m, 3H), 3.29-3.06 (m, 2H), 2.64 (s, 3H), 2.22 (s, 3H), 2.18-2.14 (m, 1H), 1.99 - 1.94 (m, 2H), 1.83 - 1.75 (m, 2H), 1.51 - 1.38 (m, 1H), 1.32-1.22 (m, 1H), 0.86 (d, *J* = 6.0 Hz, 3H).

¹⁹F NMR (400 MHz, CD₃OD): δ -69.39.

Elemental Analysis: Calcd for C₃₁H₄₃F₃N₄O₈ · H₂O: C, 55.18; H, 6.72; N, 8.30. Found: C, 54.95; H, 6.89; N, 8.07


- 25 Moisture Content (Karl Fischer): 2.33%

The elemental analysis of Compound B meglumine salt shows that it contains a one to one to ratio of Compound A cation to meglumine anion to water molecule.

CLAIMS

What is claimed is:

1. A compound of Formula (I):




Formula (I),

in the form of a hemisulfate salt.

2. The compound of claim 1 in crystalline form.
3. The compound of claim 2 characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1 or FIG. 2, wherein the X-ray powder diffraction pattern is collected using Cu K alpha (1.5406 Angstrom) radiation.
4. The compound of claim 2 characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at angles $7.3 \pm 0.2^\circ$, $14.7 \pm 0.2^\circ$, $19.1 \pm 0.2^\circ$, and $22.3 \pm 0.2^\circ$, wherein the X-ray powder diffraction pattern is collected using Cu K alpha (1.5406 Angstrom) radiation.
5. The compound of claim 4 characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at one or more of angles $8.3 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, $16.5 \pm 0.2^\circ$, $19.7 \pm 0.2^\circ$, or $25.8 \pm 0.2^\circ$, wherein the X-ray powder diffraction pattern is collected using Cu K alpha (1.5406 Angstrom) radiation.
6. The compound of claim 2 characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at angles $6.7 \pm 0.2^\circ$, $13.5 \pm 0.2^\circ$, $17.4 \pm 0.2^\circ$, and $18.1 \pm 0.2^\circ$, wherein the X-ray powder diffraction pattern is collected using Cu K alpha (1.5406 Angstrom) radiation.
7. The compound of claim 6 further characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at one or more of angles $14.5 \pm 0.2^\circ$, $16.1 \pm 0.2^\circ$, $22.4 \pm 0.2^\circ$, $23.2 \pm 0.2^\circ$, or $23.4 \pm 0.2^\circ$, wherein the X-ray powder diffraction pattern is collected using Cu K alpha (1.5406 Angstrom) radiation.
8. The compound of any one of claims 2–7, wherein greater than 90% of the compound is in crystalline form.

9. A compound of Formula (II):



Formula (II),

in the form of a meglumine salt or a hydrate of the meglumine salt.

10. The compound of claim 9, wherein the compound is in the form of a monohydrate.

11. The compound of claim 9, wherein the compound is unhydrated.

12. A pharmaceutical composition comprising a compound of any one of claims 1–11 and a pharmaceutically acceptable excipient.

13. A therapeutically effective amount of a compound of any one of claims 1–11, or a pharmaceutical composition of claim 12 for use in therapy.

14. Use of a therapeutically effective amount of a compound of any one of claims 1–11, or a pharmaceutical composition of claim 12 in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the medicament is to be administered to the subject in need thereof, wherein the PPAR δ related disease is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a mitochondrial disease, a beta oxidation disease, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease.

15. The use of claim 14, wherein:

the muscle structure disorder is selected from Bethlem myopathy, central core disease, congenital fiber type disproportion, distal muscular dystrophy (MD), Duchenne & Becker MD, Emery-Dreifuss MD, facioscapulohumeral MD, hyaline body myopathy, limb-girdle MD, a muscle sodium channel disorders, myotonic chondrodystrophy, myotonic dystrophy, myotubular myopathy, nemaline body disease, oculopharyngeal MD, or stress urinary incontinence;

the neuronal activation disorder is selected from amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Guillain-Barre syndrome, Lambert-Eaton syndrome, multiple sclerosis,

myasthenia gravis, nerve lesion, peripheral neuropathy, spinal muscular atrophy, tardy ulnar nerve palsy, or toxic myoneural disorder;

the muscle fatigue disorder is selected from chronic fatigue syndrome, glycogen storage disease, fibromyalgia, Friedreich's ataxia, intermittent claudication, lipid storage myopathy, MELAS, mucopolysaccharidosis, Pompe disease, or thyrotoxic myopathy; the muscle mass disorder is cachexia, cartilage degeneration, cerebral palsy, compartment syndrome, critical illness myopathy, inclusion body myositis, muscular atrophy (disuse), sarcopenia, steroid myopathy, or systemic lupus erythematosus;

the mitochondrial disease is selected from Alpers's Disease, CPEO-Chronic progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes, MERRF-Myoclonic epilepsy and ragged-red fiber disease, NARP-neurogenic muscle weakness, ataxia, and retinitis pigmentosa, or Pearson Syndrome;

the beta oxidation disease is selected from carnitine palmitoyltransferase (CPT) II deficiency, very long-chain acyl-CoA dehydrogenase (LCHAD or VLCAD) deficiency, trifunctional enzyme deficiency, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, short-chain acyl-CoA dehydrogenase (SCAD) deficiency or riboflavin-responsive disorders of β -oxidation (RR -MADD);

the metabolic disease is selected from hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, HDL hypocholesterolemia, LDL hypercholesterolemia, VLDL hyperproteinemia, dyslipoproteinemia, apolipoprotein A-I hypoproteinemia, atherosclerosis, disease of arterial sclerosis, disease of cardiovascular systems, cerebrovascular disease, peripheral circulatory disease, metabolic syndrome, syndrome X, obesity, diabetes (type I or II), hyperglycemia, insulin resistance, impaired glucose tolerance, hyperinsulinism, diabetic complication, cardiac insufficiency, cardiac infarction, cardiomyopathy, hypertension, Non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), thrombus, Alzheimer disease, neurodegenerative disease, demyelinating disease, adrenoleukodystrophy, dermatitis, psoriasis, acne, trichosis, inflammation, arthritis, asthma, hypersensitive intestine syndrome, ulcerative colitis, Crohn's disease, or pancreatitis;

the cancer is a cancer of the colon, large intestine, skin, breast, prostate, ovary, or lung;

the vascular disease is selected from peripheral vascular insufficiency, peripheral vascular disease, intermittent claudication, peripheral vascular disease (PVD), peripheral

artery disease (PAD), peripheral artery occlusive disease (PAOD), or peripheral obliterative arteriopathy;

the ocular vascular disease is selected from age-related macular degeneration (AMD), stargardt disease, hypertensive retinopathy, diabetic retinopathy, retinopathy, macular degeneration, retinal haemorrhage, or glaucoma;

the muscular eye disease is selected from strabismus, progressive external ophthalmoplegia, esotropia, exotropia, a disorder of refraction and accommodation, hypermetropia, myopia, astigmatism, anisometropia, presbyopia, a disorders of accommodation, or internal ophthalmoplegia; and

the renal disease is selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury, chronic renal failure, diabetic nephropathy, or Bartter's syndrome.

16. Use of a therapeutically effective amount of a compound of any one of claims 1–8, or a pharmaceutical composition comprising a compound of any one of claims 1–8 and a pharmaceutically acceptable excipient, in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the PPAR δ related disease or condition is Duchenne Muscular Dystrophy.

17. Use of a therapeutically effective amount of a compound of any one of claims 9–11, or a pharmaceutical composition comprising a compound of any one of claims 9–11 and a pharmaceutically acceptable excipient, in the manufacture of a medicament for the treatment of a PPAR δ related disease or condition in a subject, wherein the PPAR δ related disease or condition is acute kidney injury.